ATC code C10
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup C10 is part of the anatomical group C Cardiovascular system.[4]
| ATC code C: Cardiovascular system |
|---|
|
| Other ATC codes |
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC10.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
C10A Lipid modifying agents, plain
C10AA HMG CoA reductase inhibitors
- C10AA01 Simvastatin
- C10AA02 Lovastatin
- C10AA03 Pravastatin
- C10AA04 Fluvastatin
- C10AA05 Atorvastatin
- C10AA06 Cerivastatin
- C10AA07 Rosuvastatin
- C10AA08 Pitavastatin
C10AB Fibrates
- C10AB01 Clofibrate
- C10AB02 Bezafibrate
- C10AB03 Aluminium clofibrate
- C10AB04 Gemfibrozil
- C10AB05 Fenofibrate
- C10AB06 Simfibrate
- C10AB07 Ronifibrate
- C10AB08 Ciprofibrate
- C10AB09 Etofibrate
- C10AB10 Clofibride
- C10AB11 Choline fenofibrate
C10AC Bile acid sequestrants
- C10AC01 Colestyramine
- C10AC02 Colestipol
- C10AC03 Colextran
- C10AC04 Colesevelam
C10AD Nicotinic acid and derivatives
- C10AD01 Niceritrol
- C10AD02 Nicotinic acid
- C10AD03 Nicofuranose
- C10AD04 Aluminium nicotinate
- C10AD05 Nicotinyl alcohol (pyridylcarbinol)
- C10AD06 Acipimox
- C10AD52 Nicotinic acid, combinations
C10AX Other lipid modifying agents
- C10AX01 Dextrothyroxine
- C10AX02 Probucol
- C10AX03 Tiadenol
- C10AX05 Meglutol
- C10AX06 Omega-3-triglycerides
- C10AX07 Magnesium pyridoxal 5-phosphate glutamate
- C10AX08 Policosanol
- C10AX09 Ezetimibe
- C10AX10 Alipogene tiparvovec
- C10AX11 Mipomersen
- C10AX12 Lomitapide
- C10AX13 Evolocumab
- C10AX14 Alirocumab
- C10AX15 Bempedoic acid
- C10AX16 Inclisiran
- C10AX17 Evinacumab
- C10AX18 Volanesorsen
C10B Lipid modifying agents, combinations
C10BA Combinations of various lipid modifying agents
- C10BA01 Lovastatin and nicotinic acid
- C10BA02 Simvastatin and ezetimibe
- C10BA03 Pravastatin and fenofibrate
- C10BA04 Simvastatin and fenofibrate
- C10BA05 Atorvastatin and ezetimibe
- C10BA06 Rosuvastatin and ezetimibe
- C10BA07 Rosuvastatin and omega-3 fatty acids
- C10BA08 Atorvastatin and omega-3 fatty acids
- C10BA09 Rosuvastatin and fenofibrate
- C10BA10 Bempedoic acid and ezetimibe
- C10BA11 Pravastatin and ezetimibe
- C10BA12 Pravastatin, ezetimibe and fenofibrate
C10BX Lipid modifying agents in combination with other drugs
- C10BX01 Simvastatin and acetylsalicylic acid
- C10BX02 Pravastatin and acetylsalicylic acid
- C10BX03 Atorvastatin and amlodipine
- C10BX04 Simvastatin, acetylsalicylic acid and ramipril
- C10BX05 Rosuvastatin and acetylsalisylic acid
- C10BX06 Atorvastatin, acetylsalicylic acid and ramipril
- C10BX07 Rosuvastatin, amlodipine and lisinopril
- C10BX08 Atorvastatin and acetylsalicylic acid
- C10BX09 Rosuvastatin and amlodipine
- C10BX10 Rosuvastatin and valsartan
- C10BX11 Atorvastatin, amlodipine and perindopril
- C10BX12 Atorvastatin, acetylsalicylic acid and perindopril
- C10BX13 Rosuvastatin, perindopril and indapamide
- C10BX14 Rosuvastatin, amlodipine and perindopril
- C10BX15 Atorvastatin and perindopril
- C10BX16 Rosuvastatin and fimasartan
- C10BX17 Rosuvastatin and ramipril
- C10BX18 Atorvastatin, amlodipine and ramipril
- C10BX19 Atorvastatin, amlodipine and candesartan
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code C10". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QC10". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.